Clinical Outcomes of People With Fabry Disease - ANZDATA Registry Study.
作者信息
Ng Monica S, Malacova Eva, Hurst Cameron, Johnson David W, Mallett Andrew J
机构信息
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Kidney Health Service, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland, Australia.
出版信息
Kidney Int Rep. 2021 Jun 29;6(9):2481-2485. doi: 10.1016/j.ekir.2021.06.013. eCollection 2021 Sep.
Abstract
摘要
相似文献
1
Clinical Outcomes of People With Fabry Disease - ANZDATA Registry Study.
Kidney Int Rep. 2021 Jun 29;6(9):2481-2485. doi: 10.1016/j.ekir.2021.06.013. eCollection 2021 Sep.
2
Validity of registry data: agreement between cancer records in an end-stage kidney disease registry (voluntary reporting) and a cancer register (statutory reporting).
Nephrology (Carlton). 2010 Jun;15(4):491-501. doi: 10.1111/j.1440-1797.2010.01297.x.
3
Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.
BMC Nephrol. 2019 Nov 21;20(1):417. doi: 10.1186/s12882-019-1605-6.
4
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Nephrol Dial Transplant. 2010 Mar;25(3):769-75. doi: 10.1093/ndt/gfp554. Epub 2009 Oct 21.
5
Comparison of cause of death between Australian and New Zealand Dialysis and Transplant Registry and the Australian National Death Index.
Nephrology (Carlton). 2019 Mar;24(3):322-329. doi: 10.1111/nep.13250.
6
End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases.
BMC Nephrol. 2012 Dec 3;13:164. doi: 10.1186/1471-2369-13-164.
7
Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry.
PLoS One. 2019 Aug 23;14(8):e0221531. doi: 10.1371/journal.pone.0221531. eCollection 2019.
8
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13.
9
Corrigendum to Ng MS, Malacova E, Hurst C, David MC, Johnson DW, Mallett AJ. "Clinical Outcomes of People With Fabry Disease - ANZDATA Registry Study." . 2021;6:2481-2485.
Kidney Int Rep. 2022 Feb 10;7(3):664. doi: 10.1016/j.ekir.2022.02.006. eCollection 2022 Mar.
10
Comorbidity recording and predictive power of comorbidities in the Australia and New Zealand dialysis and transplant registry compared with administrative data: 2000-2010.
Nephrology (Carlton). 2016 Nov;21(11):930-937. doi: 10.1111/nep.12694.
引用本文的文献
1
Electrocardiographic abnormalities attributable to infiltrative cardiomyopathies: review and prevalence in patients with congestive heart failure.
Clin Res Cardiol. 2024 Oct 28. doi: 10.1007/s00392-024-02568-2.
2
People with genetic kidney diseases on kidney replacement therapy have different clinical outcomes compared to people with other kidney diseases.
Sci Rep. 2024 Mar 21;14(1):6746. doi: 10.1038/s41598-024-57273-x.
3
Monogenic Kidney Diseases in Kidney Transplantation.
Kidney Int Rep. 2023 Dec 13;9(3):549-568. doi: 10.1016/j.ekir.2023.12.003. eCollection 2024 Mar.
4
Outcomes and management of kidney transplant recipients with Fabry disease: a review.
J Nephrol. 2024 Apr;37(3):561-571. doi: 10.1007/s40620-023-01853-z. Epub 2024 Jan 16.
本文引用的文献
1
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75.
2
Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.
Genet Med. 2009 Nov;11(11):790-6. doi: 10.1097/GIM.0b013e3181bb05bb.
3
Kidney transplantation in patients with Fabry disease.
Transpl Int. 2009 Apr;22(4):475-81. doi: 10.1111/j.1432-2277.2008.00824.x. Epub 2009 Jan 22.
4
Kidney transplant outcomes in patients with Fabry disease.
Transplantation. 2009 Jan 27;87(2):280-5. doi: 10.1097/TP.0b013e318191a842.
5
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Nephrol Dial Transplant. 2008 May;23(5):1628-35. doi: 10.1093/ndt/gfm813. Epub 2007 Dec 5.
6
Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Am J Kidney Dis. 2005 Jul;46(1):120-7. doi: 10.1053/j.ajkd.2005.03.016.
7
Patients with Fabry disease on dialysis in the United States.
Kidney Int. 2002 Jan;61(1):249-55. doi: 10.1046/j.1523-1755.2002.00097.x.
8
Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
Nephrol Dial Transplant. 1996;11 Suppl 7:4-20. doi: 10.1093/ndt/11.supp7.4.
9
Progressive cardiac involvement by Fabry's disease despite successful renal allotransplantation.
Int J Cardiol. 1985 Jan;7(1):72-5. doi: 10.1016/0167-5273(85)90179-2.
Zotero 插件